Form 4: STERIS Executive Reports Routine Share Vesting and Tax-Related Disposition

Cary L. Majors, SVP and President of Healthcare at STERIS plc, reported the vesting of restricted shares and a subsequent tax-related disposition of 564 ordinary shares at $242.08 per share.

Summary

• Cary L. Majors, SVP and President, Healthcare of STERIS plc, reported a transaction on June 2, 2025, involving the vesting of restricted shares.
• 564 ordinary shares were disposed of to cover tax obligations related to the vesting of 1,964 restricted shares.
• The shares were valued at the NYSE closing market price of $242.08 on June 2, 2025.
• These 1,964 restricted shares were originally awarded to Mr. Majors on June 2, 2021.
• Following the transaction, Mr. Majors directly beneficially owns 10,808 ordinary shares.
• Additionally, 67 ordinary share equivalents are held indirectly under the STERIS Corporation 401(k) Plan as of June 2, 2025.
• As of June 3, 2025, 7,908 of the directly held ordinary shares remain restricted, with vesting schedules extending to October 1, 2025 (692 shares), June 1, 2026 (2,697 shares), June 2, 2026 (2,140 shares), and June 4, 2027 (2,379 shares).

Sentiment

Score: 6

Explanation: The document reports a routine insider transaction related to executive compensation. The disposition of shares is for tax purposes upon vesting, which is a neutral to slightly positive event as it indicates the executive's long-term incentives are maturing. There are no negative implications for the company's operations or financial health.

Positives

• The vesting of restricted shares indicates the fulfillment of long-term incentive compensation for a key executive, aligning management interests with shareholder value.
• The disposition of shares was for tax-related withholding, a routine and non-discretionary event, which is generally viewed neutrally or positively as it's part of a standard executive compensation plan.

Future Outlook

This document primarily details a past insider transaction related to executive compensation and provides a schedule for future vesting of remaining restricted shares. It does not offer forward-looking statements or guidance regarding the company's operational or financial performance.

Industry Context

This Form 4 filing is a routine disclosure of insider stock transactions, which is a common regulatory requirement for all publicly traded companies. It reflects standard executive compensation practices involving restricted stock units and the associated tax withholding upon vesting, a prevalent method for long-term incentive alignment across various industries.

Comparison to Industry Standards

• The compensation structure involving restricted stock units (RSUs) and tax withholding upon vesting is a standard practice in executive compensation across various industries, including healthcare and medical technology, aligning with typical long-term incentive plans designed to align executive interests with shareholder value.
• This type of insider transaction (tax-related disposition) is a routine event and does not typically indicate a change in company fundamentals or executive sentiment, consistent with industry norms for managing RSU awards.

Stakeholder Impact

• Shareholders: The report indicates a routine executive compensation event, which is generally expected. The executive continues to hold a significant number of shares, aligning interests with shareholders.
• Employees: No direct impact on general employees.
• Customers/Suppliers/Creditors: No direct impact.

Next Steps

• Future vesting of remaining restricted shares for Cary L. Majors on October 1, 2025 (692 shares), June 1, 2026 (2,697 shares), June 2, 2026 (2,140 shares), and June 4, 2027 (2,379 shares).

Key Dates

Recommendation

Keywords

STERIS plc, STE, Form 4, Insider Transaction, Beneficial Ownership, Restricted Stock Units, Executive Compensation, Share Vesting, Tax Withholding